| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$83.5M | ROE | −37.82% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Tectonic Therapeutic is a biotechnology company focused on discovering and developing therapeutic proteins and antibodies to modulate G protein coupled receptors. It develops its GEODe technology platform to enable discovery of GPCR-targeted biologic medicines. Its lead product is TX45, an Fc-relaxin fusion molecule that activates the RXFP1 receptor, and it is also developing TX2100 for hereditary hemorrhagic telangiectasia and additional GPCR modulators. The company is headquartered in Watertown, Massachusetts.
| Market Cap | $562.3M | Trading Days | 523 |
| 52W High | 39.53 |
| 52W Low | 14.39 |
| % Off High | −24.61% |
| YTD | 42.86% | 1Y | 31.05% |
| Since incept. (ann.) | 328.99% |
| Ann. Volatility (1Y) | 82.47% | Ann. Volatility (3Y) | 738.42% |
| Sharpe (1Y) | 0.76 | Sharpe (3Y) | 0.80 |
| Max Drawdown (1Y) | −44.62% | Max Drawdown (3Y) | −73.25% |
| Beta (3Y, vs SPY) | 0.21 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PRME | Prime Medicine, Inc. | $558.1M | — |
| ALLO | Allogene Therapeutics, Inc. | $573.0M | — |
| ZURA | Zura Bio Ltd | $526.3M | — |
| EIKN | Eikon Therapeutics, Inc. | $513.8M | — |
| RGNX | REGENXBIO Inc. | $496.3M | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $490.3M | — |
| KYTX | Kyverna Therapeutics, Inc. | $455.4M | — |
| REPL | Replimune Group, Inc. | $449.1M | — |
| CADL | Candel Therapeutics, Inc. | $709.3M | — |
| CABA | Cabaletta Bio, Inc. | $445.1M | — |
| AURA | Aura Biosciences, Inc. |
| $728.9M |
| — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $427.0M | — |
